Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.
about
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.
P2860
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of Novel Targeted T ...... rom US FDA approved Therapies.
@en
Evaluation of Novel Targeted T ...... rom US FDA approved Therapies.
@nl
type
label
Evaluation of Novel Targeted T ...... rom US FDA approved Therapies.
@en
Evaluation of Novel Targeted T ...... rom US FDA approved Therapies.
@nl
prefLabel
Evaluation of Novel Targeted T ...... rom US FDA approved Therapies.
@en
Evaluation of Novel Targeted T ...... rom US FDA approved Therapies.
@nl
P2093
P2860
P50
P356
P1433
P1476
Evaluation of Novel Targeted T ...... rom US FDA approved Therapies.
@en
P2093
Cynthia E Herzog
David S Hong
Joseph A Ludwig
Kenneth R Hess
Michael J Wagner
Muhammad Rizwan Khawaja
Robert S Benjamin
Sarina Piha-Paul
Shreyaskumar Patel
P2860
P2888
P356
10.1038/SREP35448
P407
P577
2016-10-17T00:00:00Z